Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

Conditions

• Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma
• Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer
• Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer
• Advanced Solid Tumors
• Advanced or Metastatic KRAS-mutant Tumor

Interventions

• DRUG: WEF-001

Sponsor

Auricula Biosciences Inc.

Collaborators

• [object Object]